We know. Your schedule is packed this week with NHL playoff games and early spring BBQ shenanigans. Now add to your list the two-day Federal Reserve policy meeting, a whole bunch of headline earnings reports, and Friday's big April jobs report. Despite major falls by tech stocks, the blue chip-packed Dow Jones Industrial Average (DJINDICES:^DJI) gained 87 points Monday to kick off the action-packed Wall Street week.
1. Bank of America drops after stress-test error comes to light
Whoops. Bank of America (NYSE:BAC) stock dropped 6% Monday when investors learned that the bank screwed up its "stress test" with the Federal Reserve Bank. The company admitted the mistake and said it will have to cancel its planned dividend increase and share buyback until it retakes the test.
In other words, it cheated by accident on its test. The Fed requires all banks to pass stress tests before being allowed to give dividends and other rewards to shareholders. Citigroup (NYSE:C) was embarrassed last month as one of the five banks that failed, while Bank of America rushed home to Charlotte, N.C., to show Momma its report card. But in the past weeks, BOA realized it miscalculated the value of some of its capital bonds issued by the bank's Merrill Lynch division, which unintentionally overstated the soundness of the bank.
Can you "recall" an email to the Federal Reserve Bank? No. But we feel for the analysts who screwed this up, and also for Bank of America for taking a month to notice the important error. It should be noted that the Fed didn't notice the mistake, either, in its review of Bank of America's performance, so shame on everyone.
We're sorry. The Bank decided Monday it's better to come clean about the mistake now than wait and keep fingers crossed that it goes unnoticed forever. It now has 30 days to resubmit its test. Until it proves that it can withstand another economic crisis without a bailout, there will be no increase to Bank of America's current $0.01-per-share current dividend. (Since 2008, shareholders have gotten just four pennies every year as a "reward" for owning part of the bank.)
2. Buffalo Wild Wings' spicy earnings
Slather yourself in these hot corporate earnings. Shares of food chain Buffalo Wild Wings (NASDAQ:BWLD) jumped over 4% in after-hours trading Monday after reporting a seriously satisfying first-quarter performance -- the company's $367.9 million in revenues over the past three months topped analysts' estimates of $363 million.
It's all about tech for the restaurant's new "Guest Service" initiative unveiled only a couple of months ago. Just in case you weren't already overwhelmed by the hundreds of TVs showing everything from NFL match-ups to the almighty Vanderbilt women's bowling team, Buffalo Wild Wings is adding table-side tablets for customers to play poker or trivia games while they wait. #ADD
We're serious about this initiative. Buffalo Wild Wings signed a deal with interactive entertainment firm NTM Buzztime last year and is adding "Guest Experience Captains" (terrible name) to help tech-challenged patrons. The company plans to unveil the system in each of its restaurants by 2015 -- just don't let one of Wild Wings' 16 corn fructose-enhanced sauces ruin your screen.
Interestingly, CEO Sally Smith disclosed that she sold over $214,000 of Wild Wings stock over the past week, leaving her equity stake worth around $11.4 million. Keep in mind that C-level execs and other insiders can't just drop their stock all willy nilly -- these VIPs with sensitive information on the company are restricted on selling their stock during certain periods of time and have to file with the SEC before officially dropping their stock on the market.
3. Pfizer wants to acquire British drug giant AstraZeneca
New York's biggest drug company is not 16 Handles (even though we swear that stuff is addicting). It's Pfizer (NYSE:PFE), and the Big Apple-based pharmaceutical firm wants to get bigger. The company announced that it's offering $99 billion to acquire British AstraZeneca. It would break the record Pfizer already holds for biggest takeover in the pharma industry, if the Brits agree to it.
If the deal goes down, Pfizer would jump across the pond to England. Pfizer said the combined company, while majority-owned by Pfizer shareholders, would reincorporate in the UK. This would save the company taxes and keep some proud Brits happy.
AstraZeneca is known for its prescription cholesterol medication Crestor, but it also has a nice portfolio of cancer treatment drugs, a focus for Pfizer. AstraZeneca's shares jumped 16% since Pfizer wants it so badly.
Pfizer made big profits with Lipitor until 2011. Then its patent ran out. This acquisition would bring in a ton of different revenue sources for the huge company so that its livelihood depended less on patented drugs that are eventually drowned in generic versions. AstraZeneca's board (which we imagine are in pinstriped suits with Union Jack cufflinks) is asking shareholders to be patient and let it make a recommendation before voting on Pfizer's offer.
- The two-day Fed policy meeting begins.
- First-quarter corporate rarnings: Coach, eBay, Merck.
MarketSnacks Fact of the Day: In 2011, popular cinnamon-flavored Fireball whiskey had $1.9 million in sales -- by 2013 the beverage enjoyed a whopping $61 million in sales, putting it ahead of Jameson Irish Whiskey and Patron tequila.
As originally published on MarketSnacks.com
Jack Kramer and Nick Martell have no position in any stocks mentioned. The Motley Fool recommends Bank of America, Buffalo Wild Wings, Coach, and eBay and owns shares of Bank of America, Buffalo Wild Wings, Citigroup, Coach, and eBay. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Does a Strong Start Make 2018 a Sure Winner for Stocks?
Find out whether the so-called "January effect" is real.
Meet the 2018 Dogs of the Dow
Learn the basics of this simple dividend-investing strategy.
The Dow's Worst Day in 2017
Even with big gains, there were some scary times for the average.